한글목차

옥트레오타이드는 합성 소마토스타틴 유사체로, 혈관 활성 장 펩타이드(VIP)와 같은 많은 호르몬의 분비 감소, 장 통과 시간 연장, 수분 및 전해질 분비 감소 및 흡수 증가와 같은 여러 메커니즘을 통해 작용합니다. 미국 식품의약국(FDA)에서 VIP 분비 종양과 관련된 설사 및 카르티노이드 증후군으로 인한 증상 치료제로 승인되었습니다. 옥트레오타이드는 플루오로피리미딘, 일리노테칸 및 5-FU 기반 화학방사선요법으로 CID 환자에게 유익하며, 5-FU 치료 환자 41명을 대상으로 한 1건의 무작위 시험에서 옥트레오타이드가 표준 용량의 로페라미드보다 더 효과적임이 입증되었습니다(3일째까지). 설사 소실률 90% 대 15%), 옥트레오타이드는 비용이 비싸기 때문에 일반적으로 로페라미드 증량에도 불구하고 48시간 후 반응하지 않는 환자들에게 2차 선택 치료제로 사용됩니다. 심한 설사, 메스꺼움, 구토, 식욕부진, 복부 경련과 같은 소화기 증후군이 발생한 환자는 정맥주사 및 옥트레오타이드의 사전 투여를 통해 적극적으로 관리해야 합니다.

앞으로 몇 년동안 화학요법 유발성 설사(CID) 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 옥트레오타이드의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, CID에 대한 다른 신흥 제품들이 옥트레오타이드와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 출시가 시장에 큰 영향을 미칠 것으로 예상되고 있습니다.

이 보고서는 주요 7개국의 화학요법 유발성 설사(CID) 치료제 옥트레오타이드(Octreotide) 시장을 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 CID 치료제 옥트레오타이드 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 옥트레오타이드 시장 평가

• CID 치료제 옥트레오타이드 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 CID 치료제 옥트레오타이드 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"Octreotide Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about octreotide for Chemotherapy-induced Diarrhea (CID) in the seven major markets. A detailed picture of the octreotide for CID in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the octreotide for CID. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the octreotide market forecast analysis for CID in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CID.

Drug Summary:

Octreotide, a synthetic somatostatin analog, acts via several mechanisms: decreased secretion of a number of hormones, such as vasoactive intestinal peptide (VIP); prolongation of intestinal transit time and reduced secretion and increased absorption of fluid and electrolytes. It is approved by the US Food and Drug Administration for the treatment of diarrhea related to VIP-secreting tumors and symptoms due to carcinoid syndrome. Octreotide is beneficial in patients with CID from fluoropyrimidines, irinotecan, and 5-FU-based chemoradiotherapy. Although one randomized trial in 41 5-FU-treated patients showed that octreotide was more effective than standard-dose loperamide (90 versus 15% resolution of diarrhea by day 3), octreotide is generally reserved as a second-line treatment for patients who are refractory after 48 hours, despite a loperamide escalation, because of its high cost. Patients developing a gastrointestinal syndrome including severe diarrhea, nausea, vomiting, anorexia, and abdominal cramping should receive an aggressive management with intravenous fluids and upfront octreotide.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the octreotide description, mechanism of action, dosage and administration, research and development activities in Chemotherapy-induced Diarrhea (CID).
• Elaborated details on octreotide regulatory milestones and other development activities have been provided in this report.
• The report also highlights the octreotide research and development activities in CID across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around octreotide.
• The report contains forecasted sales of octreotide for CID till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CID.
• The report also features the SWOT analysis with analyst views for octreotide in CID.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Octreotide Analytical Perspective by DelveInsight

• In-depth Octreotide Market Assessment

This report provides a detailed market assessment of octreotide for Chemotherapy-induced Diarrhea (CID) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Octreotide Clinical Assessment

The report provides the clinical trials information of octreotide for CID covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chemotherapy-induced Diarrhea (CID) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence octreotide dominance.
• Other emerging products for CID are expected to give tough market competition to octreotide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of octreotide in CID.
• Our in-depth analysis of the forecasted sales data of octreotide from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the octreotide in CID.

Key Questions:

• What is the product type, route of administration and mechanism of action of octreotide?
• What is the clinical trial status of the study related to octreotide in Chemotherapy-induced Diarrhea (CID) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the octreotide development?
• What are the key designations that have been granted to octreotide for CID?
• What is the forecasted market scenario of octreotide for CID?
• What are the forecasted sales of octreotide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to octreotide for CID?
• Which are the late-stage emerging therapies under development for the treatment of CID?

Table of Contents

1. Report Introduction

2. Octreotide Overview in CID

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Octreotide Market Assessment

• 5.1. Market Outlook of Octreotide in CID
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Octreotide in the 7MM for CID
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Octreotide in the United States for CID
  • 5.3.2. Market Size of Octreotide in Germany for CID
  • 5.3.3. Market Size of Octreotide in France for CID
  • 5.3.4. Market Size of Octreotide in Italy for CID
  • 5.3.5. Market Size of Octreotide in Spain for CID
  • 5.3.6. Market Size of Octreotide in the United Kingdom for CID
  • 5.3.7. Market Size of Octreotide in Japan for CID

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options